Pfizer and BioNTech on Monday said trial results proved their Covid-10 vaccine was safe and produced a robust immune response in kids aged five to 11, adding that they would seek regulatory approval shortly. The vaccine would be administered at a lower dosage than for people over 12, they said. "In participants 5 to 11 years of age, the vaccine was safe, well-tolerated and showed strong neutralising antibody responses," US giant Pfizer and its German partner said in a joint statement.
The trial results are the first of their kind for children under 12, with a Moderna trial for six-11-year-olds still ongoing. They plan to submit their data to regulatory bodies in the European Union, the United States and around the world "as soon as possible". Both the Pfizer and Moderna vaccines are already being administered to adolescents over 12 and adults in countries around the globe. Although children are considered less at risk of severe Covid, there are concerns that the highly contagious Delta variant could lead to more serious cases.
Children in the 5-11 age trial group received a two-dose regimen of 10 micro-grammes in the trial, compared with 30 microgrammes for older age groups, the companies said. The shots were given 21 days apart. The 10 microgramme dose was "carefully selected as the preferred dose for safety, tolerability and immunogenicity" for that age group, the statement said.